DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations
- PMID:7795587
- DOI: 10.1093/hmg/4.3.351
DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations
Abstract
Constitutional point mutations in the zinc finger (ZF) region of the Wilms' tumour suppressor gene 1 (WT1) lead to Denys-Drash syndrome (DDS). Patients with this syndrome display renal failure, Wilms' tumour (WT) and pseudohermaphroditism. DDS WT1 mutations fall into three major categories: (a) missense mutations altering amino acids which directly interact with the DNA target; (b) substitution of amino acids involved in zinc complexing; and (c) nonsense mutations leading to the removal of at least two zinc fingers. We have expressed the WT1 zinc fingers as glutathione-S-transferase fusion proteins, with the lysine-threonine-serine (KTS) alternate splice between ZF3 and ZF4 either present or absent. WT1 fusion constructs with all three classes of DDS mutation were also created. Wild-type and mutant fusion proteins were assayed for their DNA-binding affinity using four previously identified WT1 DNA targets: an EGR1 consensus site; murine insulin-like growth factor 2 promoter 2 (IGF2P2); a (TCC)n motif from the PDGFA-chain promoter; and +P5, a genomic fragment isolated by its affinity for WT1 + KTS. WT1-KTS bound all four targets, but WT1 + KTS only bound +P5. All three classes of DDS mutation investigated, with or without KTS, abolished binding to all four targets. This provides evidence that DDS mutations act either as dominant-negative antimorphs, or elicit their effect through disturbed isoform dosage balance.
Similar articles
- Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.Borel F, Barilla KC, Hamilton TB, Iskandar M, Romaniuk PJ.Borel F, et al.Biochemistry. 1996 Sep 17;35(37):12070-6. doi: 10.1021/bi960758o.Biochemistry. 1996.PMID:8810912
- A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.Little MH, Holmes G, Pell L, Caricasole A, Duarte A, Law M, Ward A, Wainwright B.Little MH, et al.Oncogene. 1996 Oct 3;13(7):1461-9.Oncogene. 1996.PMID:8875984
- WT1 mutations in patients with Denys-Drash syndrome: a novel mutation in exon 8 and paternal allele origin.Nordenskjöld A, Friedman E, Anvret M.Nordenskjöld A, et al.Hum Genet. 1994 Feb;93(2):115-20. doi: 10.1007/BF00210593.Hum Genet. 1994.PMID:8112732
- An unusual phenotype of Frasier syndrome due to IVS9 +4C>T mutation in the WT1 gene: predominantly male ambiguous genitalia and absence of gonadal dysgenesis.Melo KF, Martin RM, Costa EM, Carvalho FM, Jorge AA, Arnhold IJ, Mendonca BB.Melo KF, et al.J Clin Endocrinol Metab. 2002 Jun;87(6):2500-5. doi: 10.1210/jcem.87.6.8521.J Clin Endocrinol Metab. 2002.PMID:12050205Review.
- Frasier syndrome, part of the Denys Drash continuum or simply a WT1 gene associated disorder of intersex and nephropathy?Koziell A, Charmandari E, Hindmarsh PC, Rees L, Scambler P, Brook CG.Koziell A, et al.Clin Endocrinol (Oxf). 2000 Apr;52(4):519-24. doi: 10.1046/j.1365-2265.2000.00980.x.Clin Endocrinol (Oxf). 2000.PMID:10762296Review.
Cited by
- A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome.Patek CE, Little MH, Fleming S, Miles C, Charlieu JP, Clarke AR, Miyagawa K, Christie S, Doig J, Harrison DJ, Porteous DJ, Brookes AJ, Hooper ML, Hastie ND.Patek CE, et al.Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2931-6. doi: 10.1073/pnas.96.6.2931.Proc Natl Acad Sci U S A. 1999.PMID:10077614Free PMC article.
- Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis--a review.Löwik MM, Groenen PJ, Levtchenko EN, Monnens LA, van den Heuvel LP.Löwik MM, et al.Eur J Pediatr. 2009 Nov;168(11):1291-304. doi: 10.1007/s00431-009-1017-x. Epub 2009 Jun 27.Eur J Pediatr. 2009.PMID:19562370Free PMC article.Review.
- WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.Yang Y, Jeanpierre C, Dressler GR, Lacoste M, Niaudet P, Gubler MC.Yang Y, et al.Am J Pathol. 1999 Jan;154(1):181-92. doi: 10.1016/S0002-9440(10)65264-9.Am J Pathol. 1999.PMID:9916932Free PMC article.
- Novel mutations in steroid-resistant nephrotic syndrome diagnosed in Tunisian children.Mbarek IB, Abroug S, Omezzine A, Pawtowski A, Gubler MC, Bouslama A, Harbi A, Antignac C.Mbarek IB, et al.Pediatr Nephrol. 2011 Feb;26(2):241-9. doi: 10.1007/s00467-010-1694-8. Epub 2010 Dec 2.Pediatr Nephrol. 2011.PMID:21125408
- Evaluating Established Roles, Future Perspectives and Methodological Heterogeneity for Wilms' Tumor 1 (WT1) Antigen Detection in Adult Renal Cell Carcinoma, Using a Novel N-Terminus Targeted Antibody (Clone WT49).Novacescu D, Cut TG, Cumpanas AA, Latcu SC, Bardan R, Ferician O, Secasan CC, Rusmir A, Raica M.Novacescu D, et al.Biomedicines. 2022 Apr 15;10(4):912. doi: 10.3390/biomedicines10040912.Biomedicines. 2022.PMID:35453662Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous